TP53 and neoplasm: Finally, according to previous studies, blood-based TMb (65), tumor infiltrating lymphocytes (66) and specific gene mutations such as STK11, KEAP1 and TP53 (67) have been reported as biomarkers predictive of the benefits of ICI treatment.